-

IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced it will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024, at the New York Athletic Club in New York City.

The conference offers emerging growth, and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format. During the event, Dr. Jennifer Bath, President and CEO, will be participating in one-on-one meetings with investors and analysts throughout the day. To schedule a one-on-one meeting with Dr. Jennifer Bath, please first register here for the conference. Once you are registered, you'll gain access to the platform to submit your meeting request.

About The Benchmark Company

The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm’s sales, trading, and equity research capabilities. https://www.benchmarkcompany.com.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and is known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Contacts

Investor Relations Contact

investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$nvda
$xbi
Hashtags
#AI
#DrugDiscovery
#TechBio
#antibodies
#foundationai
#generativeai
#llm

Contacts

Investor Relations Contact

investors@ipatherapeutics.com

Social Media Profiles
Linkedin
IPA on X
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

BOSTON--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Orum Ther...

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from the first day of a de...

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced the appointment of Kim Remizowski to its Board of Directors as an independent director, effective September 29, 2026. Mr. Remizowski will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under a...
Back to Newsroom